Schirrmacher V - Search Results

1

Isolation and characterization of a metastatic Eb-like tumor variant highly responsive to interleukin (IL)-2 and to combination cytokine therapy with IL-2/IL-1 beta and IL-1 beta/interferon-alpha/beta.

Gabriele L, Proietti E, Greco G, Venditti M, Gresser I, Schirrmacher V, Von Hoegen P, Testa U, Modesti A, Cianfriglia M, et al. Gabriele L, et al. Among authors: schirrmacher v. Invasion Metastasis. 1993;13(3):147-62. Invasion Metastasis. 1993. PMID: 8112975

2

Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor-specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals.

von Hoegen P, Heicappell R, Griesbach A, Altevogt P, Schirrmacher V. von Hoegen P, et al. Among authors: schirrmacher v. Invasion Metastasis. 1989;9(2):117-33. Invasion Metastasis. 1989. PMID: 2785093

3

Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN-alpha/beta.

Kaido T, Maury C, Schirrmacher V, Gresser I. Kaido T, et al. Among authors: schirrmacher v. Int J Cancer. 1994 May 15;57(4):538-43. doi: 10.1002/ijc.2910570417. Int J Cancer. 1994. PMID: 8181857

4

CD4+ helper T cells are required for resistance to a highly metastatic murine tumor.

Schild HJ, Kyewski B, Von Hoegen P, Schirrmacher V. Schild HJ, et al. Among authors: schirrmacher v. Eur J Immunol. 1987 Dec;17(12):1863-6. doi: 10.1002/eji.1830171231. Eur J Immunol. 1987. PMID: 2961578

5

New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells.

von Hoegen P, Altevogt P, Schirrmacher V. von Hoegen P, et al. Among authors: schirrmacher v. Cell Immunol. 1987 Oct 15;109(2):338-48. doi: 10.1016/0008-8749(87)90317-0. Cell Immunol. 1987. PMID: 3117377

6

Immunological and molecular characterization of an aggressive murine lymphoma variant: modulation in vitro and in vivo.

Jurianz K, von Hoegen P, Schirrmacher V. Jurianz K, et al. Among authors: schirrmacher v. Int J Oncol. 1999 Jul;15(1):71-9. doi: 10.3892/ijo.15.1.71. Int J Oncol. 1999. PMID: 10375596

7

Scattered micrometastases visualized at the single-cell level: detection and re-isolation of lacZ-labeled metastasized lymphoma cells.

Krüger A, Schirrmacher V, von Hoegen P. Krüger A, et al. Among authors: schirrmacher v. Int J Cancer. 1994 Jul 15;58(2):275-84. doi: 10.1002/ijc.2910580222. Int J Cancer. 1994. PMID: 7517921

8

Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation.

Schild H, von Hoegen P, Schirrmacher V. Schild H, et al. Among authors: schirrmacher v. Cancer Immunol Immunother. 1989;28(1):22-8. doi: 10.1007/BF00205796. Cancer Immunol Immunother. 1989. PMID: 2462467 Free PMC article.

9

Immunoresistant metastatic tumor variants can re-express their tumor antigen after treatment with DNA methylation-inhibiting agents.

Altevogt P, von Hoegen P, Schirrmacher V. Altevogt P, et al. Among authors: schirrmacher v. Int J Cancer. 1986 Nov 15;38(5):707-11. doi: 10.1002/ijc.2910380514. Int J Cancer. 1986. PMID: 3490445

10

Superiority of the ear pinna over a subcutaneous tumour inoculation site for induction of a Th1-type cytokine response.

Jurianz K, von Hoegen P, Schirrmacher V. Jurianz K, et al. Among authors: schirrmacher v. Cancer Immunol Immunother. 1998 Feb;45(6):327-33. doi: 10.1007/s002620050450. Cancer Immunol Immunother. 1998. PMID: 9490203 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

402 results

Search Page

Filters